What is Alnylam Pharmaceuticals?
RNA interference therapeutics company with $2.987B 2025 net product revenue revenue scale and public-market buying capacity.
- Category
- RNA interference therapeutics
- Headquarters
- Cambridge, MA
- Founded
- 2002
- Employees
- 2,500+
- Total funding
- Public company; no VC funding
- Status
- Nasdaq: ALNY; Public company
What is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals is a public rna interference therapeutics company headquartered in Cambridge, MA. Alnylam reported 2025 global net product revenues of $2.987 billion, up 81% from 2024, and achieved GAAP and non-GAAP profitability for the year.
Alnylam Pharmaceuticals operates in rna interference therapeutics with a portfolio that includes Amvuttra, Onpattro, Givlaari, Oxlumo. Alnylam reported 2025 global net product revenues of $2.987 billion, up 81% from 2024, and achieved GAAP and non-GAAP profitability for the year. The company employs about 2,500+ and trades as Nasdaq: ALNY, so its buying motion looks like a regulated enterprise account rather than a startup account.
Its scale comes from clinically regulated products, payer or provider relationships, recurring consumables or services, intellectual property, manufacturing quality systems, and commercial access. Customers and partners evaluate Alnylam Pharmaceuticals through clinical outcomes, regulatory execution, supply reliability, reimbursement, data security, and total cost of care.
For sellers, Alnylam Pharmaceuticals is a multi-stakeholder account. Procurement, finance, clinical, quality, regulatory, legal, privacy, security, IT, operations, commercial, and business-unit leaders can all influence vendor approval. Strong pitches connect directly to patient impact, compliance, revenue capture, operating leverage, risk reduction, uptime, or measurable productivity.
What does Alnylam Pharmaceuticals offer?
Alnylam Pharmaceuticals offers products and services across Amvuttra, Onpattro, Givlaari, Oxlumo and related healthcare workflows.
- Amvuttra· ATTR amyloidosis
- Onpattro· ATTR amyloidosis
- Givlaari· Acute hepatic porphyria
- Oxlumo· Primary hyperoxaluria type 1
- Leqvio royalties/collaboration· Cardiometabolic
- RNAi platform· Technology platform
How does Alnylam Pharmaceuticals make money?
Alnylam Pharmaceuticals earns revenue through regulated healthcare products, services, recurring consumables, software-enabled workflows, market access, and enterprise contracts.
Alnylam Pharmaceuticals earns revenue from products and services sold to healthcare systems, clinicians, payers, labs, pharmacies, governments, distributors, life-science customers, or patients depending on the business line. In 2025, that model produced $2.987B 2025 net product revenue of reported revenue scale. Growth is tied to product demand, procedure or test volumes, prescription access, installed-base utilization, new indications, geographic reach, and disciplined pricing.
Pricing is not a public self-serve tier. It is negotiated by therapy, device, test, payer coverage, account type, contract term, service level, GPO or distributor structure, reimbursement, and geography. The practical tiers are enterprise account segmentation, clinical evidence review, value-analysis committee approval, data/security review, legal terms, and renewal or tender economics.
Vendors should expect mature procurement and high evidence requirements. Budgets open when a proposal helps Alnylam Pharmaceuticals improve launch execution, manufacturing resilience, clinical operations, data quality, regulatory readiness, patient access, field productivity, cybersecurity, or cost-to-serve.
Who leads Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals is led by Yvonne Greenstreet, with finance, R&D, commercial, technology, medical, operations, and business-unit leaders shaping major enterprise decisions.
- Yvonne GreenstreetChief Executive OfficerCEO since 2021Leads Alnylam's commercial RNAi scale-up and Alnylam 2030 strategy.
- Jeff PoultonChief Financial OfficerCFO since 2019Oversees finance, capital allocation, and profitability targets.
- Akshay VaishnawPresidentSenior R&D leaderGuides RNAi platform strategy and pipeline execution.
- Tolga TangulerChief Commercial OfficerCommercial leaderRuns global commercialization and market access.
How do you contact Alnylam Pharmaceuticals's leadership?
Alnylam Pharmaceuticals publishes official Alnylam investor-relations contact route, but it does not publish verified personal executive emails for the leaders listed here. Use the official investor, media, supplier, compliance, or contact form routes rather than guessed personal addresses.
official Alnylam investor-relations contact route; personal executive email format not verifiedHow much funding has Alnylam Pharmaceuticals raised?
Alnylam Pharmaceuticals is a mature public company, not a venture-backed startup. It trades as Nasdaq: ALNY and funds growth through operating cash flow, public-market access, debt markets, partnerships, and acquisition capacity.
Alnylam Pharmaceuticals's capital history is a public-company story rather than a disclosed venture-round history. The relevant funding events are founding, public listing, major acquisitions or divestitures, retained earnings, debt capacity, R&D reinvestment, manufacturing investment, and shareholder capital allocation.
As of June 2026, the current capital lens is Nasdaq: ALNY, $2.987B 2025 net product revenue of 2025 revenue scale, and management's ability to fund launches, facilities, technology, clinical programs, supply chain, compliance, and business development. That is materially different from a startup where the next round controls hiring and tool budgets.
Seller signal: Alnylam Pharmaceuticals has enterprise buying power, but budget access is tied to risk, ROI, auditability, executive sponsorship, and integration fit. Procurement is more likely to approve projects that reduce operational friction, protect regulated workflows, improve patient or customer outcomes, or support a named business priority.
How did Alnylam Pharmaceuticals get here?
Alnylam Pharmaceuticals grew through founding, product expansion, public-market scale, strategic portfolio moves, and regulated healthcare execution.
- 2002Alnylam foundedThe company begins developing RNA interference therapeutics.
- 2004IPOAlnylam becomes a public RNAi platform company.
- 2018Onpattro approvedThe first RNAi therapeutic approval validates the platform commercially.
- 2021Yvonne Greenstreet becomes CEOAlnylam enters a scale-up phase.
- 2025$2.987B product revenueGlobal net product revenue rises 81% and the company achieves profitability.
- 2026TTR guidance increasesAlnylam guides to $4.9 billion to $5.3 billion of 2026 combined net product revenue.
Who are Alnylam Pharmaceuticals's competitors?
Alnylam Pharmaceuticals competes with large healthcare, pharma, diagnostics, life-science, and medtech companies that overlap in products, customers, procurement budgets, and clinical workflows.
- Ionis PharmaceuticalsCompetes in RNA-targeted therapeutics and rare-disease pipelines.
- Arrowhead PharmaceuticalsCompetes in RNAi therapeutics and liver-targeted medicines.
- Intellia TherapeuticsCompetes in genetic medicines and rare-disease investor attention.
- BiogenCompetes and partners in neuroscience and rare-disease commercialization.
- NovartisCommercializes Leqvio and competes in cardiometabolic specialty markets.
- Vertex PharmaceuticalsCompetes in rare disease, genetic medicine, and specialty commercialization.
Alnylam Pharmaceuticals — frequently asked questions
